BiotechTubeBiotechTube
Home/Pipeline/Biosimilar Trastuzumab

Biosimilar Trastuzumab

Breast Cancer

CommercialActive

Key Facts

Indication
Breast Cancer
Phase
Commercial
Status
Active
Company
Cipla

About Cipla

Founded in 1935, Cipla has established itself as a pioneering pharmaceutical company committed to improving global health outcomes through affordable medicines. The company operates across multiple therapeutic areas including respiratory, oncology, anti-retroviral, and complex generics, with a particular strength in inhalation products and biosimilars. Cipla's integrated business model spans from API manufacturing to finished formulations, with a growing focus on digital health solutions and specialty products for developed markets.

View full company profile

Therapeutic Areas

RespiratoryOncologyHIV/AIDSCardiologyNeurologyDermatologyGastroenterology

Other Breast Cancer Drugs

DrugCompanyPhase
Verzenio (abemaciclib)Eli LillyApproved
Pan-mutant-selective PI3Kα inhibitorNovartisAcquisition
TrodelvyRoyalty PharmaCommercial
Trastuzumab biosimilar (IBI306)Innovent BiologicsPhase 3
Ogivri (trastuzumab biosimilar)ViatrisApproved
Trastuzumab BiosimilarDr. Reddy's LaboratoriesApproved
Ogivri (Trastuzumab)BioconApproved
TamoxifenNatco PharmaApproved
ARV-027ArvinasPhase 1
Prognostic Genomic TestsEurobio ScientificCommercial
SelinexorKaryopharm TherapeuticsClinical Trials
ATNM-400Actinium PharmaceuticalsPreclinical